Mar 27, 2023

Suraj Mudichintala is a Senior Associate at Action Potential Capital which is GSK's bioelectronic medicine venture fund.

Top 3 Takeaways:

• "Our fund is different in that we invest actually directly off of GSK's balance sheet. So we're what's called an evergreen fund where we don't actually have a fund size"
• "The way...

Mar 20, 2023

Balint Varkuti is the CEO of CereGate which unlocks new capabilities for existing neuromodulation technologies using software.

Top 3 Takeaways:

• "the brain is naturally wired for pattern perception for learning, and that's really what we do. We send signals that the brain very quickly can pick up."
• "You do not need to...

Mar 13, 2023

Kevin Tracey returns to the podcast to give an update about his work at the Feinstein Institutes and the work at SetPoint Medical.

Top 3 Takeaways:

• "Two years we discovered that a drug called Famotidine, which is sold as a generic drug Pepcid AC is actually a pharmacological or a drug-based vagus nerve stimulator. And...

Mar 6, 2023

Israel Gasperin is the founder and CEO of Zentrela which uses wearable EEG caps to quantitatively measure cannabis experiences.

Top 3 Takeaways:

• "The reason why the government funded us was to use this for safety and law enforcement"
• "The combination of features that AI is finding is something that we haven't really...

Feb 13, 2023

Colin Kealey is the President and CEO of NeuroSigma which is commercializing the Monarch eTNS System, the first non-drug treatment for pediatric ADHD cleared by the FDA. 

Top 3 Takeaways:

• NeuroSigma is commercializing the Monarch eTNS system, a wearable medical device that stimulates the trigeminal nerve on the...